Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract. Cytokine-targeted therapies have transformed the treatment of IBD, providing control of symptoms and longer relapse-free periods. However, many patients fail to respond, highlighting the need for therapies tailored to the underlying cell and molecular disease drivers. Here we discuss the progression of IBD from the perspective of remodeling of cytokine networks. We place well-established and under-studied cytokine modules in the context of cellular interactions, their dynamic regulation in early and late stages of disease (i.e., fibrosis), and their current and potential use in the clinic. Examining how particular cytokine networks drive distinct features and phases of IBD will shed light on the etiology of IBD and provide a basis for more effective treatments.

Original publication

DOI

10.1016/j.immuni.2019.03.017

Type

Journal article

Journal

Immunity

Publication Date

16/04/2019

Volume

50

Pages

992 - 1006

Keywords

Animals, Antirheumatic Agents, Cytokines, Disease Progression, Drug Resistance, Epithelial Cells, Genetic Association Studies, Homeostasis, Humans, Immunity, Innate, Inflammatory Bowel Diseases, Intestines, Lymphocyte Subsets, Mice, Myeloid Cells, STAT3 Transcription Factor, Single-Cell Analysis, Tumor Necrosis Factor-alpha